Showing results (151-160 of 238) with videos related to

Sort By:
Pageof 24
Journal of Neuromuscular Diseases|January 18, 2021
Results from a 3-year Non-interventional, Observational Disease Monitoring Program in Adults with GNE MyopathyHanns Lochmüller, Anthony Behin, Ivailo Tournev, et al.
Nature Communications|April 1, 2022
Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primatesVincent Pavot, Catherine Berry, Michael Kishko, et al.
Stem Cells (Dayton, Ohio)|January 1, 1994
Predictive statistics and artificial intelligence in the U.S. National Cancer Institute's Drug Discovery Program for Cancer and AIDSJ N Weinstein, T Myers, J Buolamwini, et al.
International Urology and Nephrology|January 29, 2024
Predictive tissue markers in testicular germ cell tumors: Immunohistochemical expression of MLH1 and REV-7 proteinsTheodoros Spinos, Eleni Zografos, Konstantinos Koutsoukos, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|September 18, 2012
Toxicology, biodistribution and shedding profile of a recombinant measles vaccine vector expressing HIV-1 antigens, in cynomolgus macaquesClarisse Lorin, Lawrence Segal, Johann Mols, et al.
The Journal of General Virology|January 17, 2008
Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combinationGerrit Koopman, Daniella Mortier, Sam Hofman, et al.
Journal of Immunological Methods|September 17, 2014
Processing of blood samples influences PBMC viability and outcome of cell-mediated immune responses in antiretroviral therapy-naïve HIV-1-infected patientsPatricia Bourguignon, Frédéric Clément, Frédéric Renaud, et al.
Nature Communications|March 9, 2023
Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primatesVincent Pavot, Catherine Berry, Michael Kishko, et al.
International Journal of Clinical Oncology|October 31, 2018
The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker studyAristotelis Bamias, Vasilios Karavasilis, Nikolaos Gavalas, et al.
Vaccine|February 15, 2008
Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteersPierre Vandepapelière, Yves Horsmans, Philippe Moris, et al.
Pageof 24